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Abstract
Staphylococcus aureus produces a high number of RNAs for which the functions are poorly understood. Several non-coding
RNAs carry a C-rich sequence suggesting that they regulate mRNAs at the post-transcriptional level. We demonstrate that
the Sigma B-dependent RsaA RNA represses the synthesis of the global transcriptional regulator MgrA by forming an
imperfect duplex with the Shine and Dalgarno sequence and a loop-loop interaction within the coding region of the target
mRNA. These two recognition sites are required for translation repression. Consequently, RsaA causes enhanced production
of biofilm and a decreased synthesis of capsule formation in several strain backgrounds. These phenotypes led to a
decreased protection of S. aureus against opsonophagocytic killing by polymorphonuclear leukocytes compared to the
mutant strains lacking RsaA. Mice animal models showed that RsaA attenuates the severity of acute systemic infections and
enhances chronic catheter infection. RsaA takes part in a regulatory network that contributes to the complex interactions of
S. aureus with the host immune system to moderate invasiveness and favour chronic infections. It is the first example of a
conserved small RNA in S. aureus functioning as a virulence suppressor of acute infections. Because S. aureus is essentially a
human commensal, we propose that RsaA has been positively selected through evolution to support commensalism and
saprophytic interactions with the host.
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Introduction
Staphylococcus aureus is an opportunistic pathogen that has evolved
complex regulatory circuits allowing rapid adaption of cell growth
in response to its diverse hosts and ecological niches. Present in a
large proportion of the population as a commensal of skin and nose,
the bacteria is also responsible for a large range of hospital-acquired
and community infections [1]. A successful infection by S. aureus
largely depends on the coordinated and sequential expression of a
multitude of virulence factors and accessory genes. Over the last
decade, it has been established that S. aureus genes are regulated at
many different levels by a variety of trans-acting regulators, which
act in a coordinated manner [2,3]. Among them, RNAs are now
recognized as important players in virulence and many physiolog-
ical and adaptive responses [4,5]. The first regulatory RNA that was
discovered in 1993 is RNAIII, the main intracellular effector of the
quorum sensing agr system [6]. This multi-functional regulatory
RNA binds to several target mRNAs to regulate their translation
and decay [7–11]. Later on, several teams have experimentally
identified a large number of small RNAs (sRNA) that are issued
from the core genome and from mobile and accessory elements
(e.g., [12,13]). These sRNAs include cis-acting regulatory regions of
mRNAs (the so-called riboswitches), cis-encoding antisense RNAs
(asRNA), and non-coding RNAs (ncRNAs). In addition, sRNAs
carrying small open reading frames (sORF) have been recently
identified [14–17] and one of them was shown to express a small
cytolytic peptide [17]. The functional and mechanistic studies of
trans-acting sRNAs are still lagging behind their discovery, but some
of them are known to sense population density and various
environmental changes, modify cell surface properties, adjust the
bacterial metabolism during cell growth, regulate virulence gene
expression, and respond to antibiotic treatment [4,18].
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We have previously identified a group of sRNAs that carry a
conserved and unpaired UCCC sequence suggesting that they act
through a common regulatory mechanism [12–14,19–23]. This
sequence motif is located in several hairpin loops of S. aureus
RNAIII and was demonstrated to be the seed sequence, which
recognizes the ribosome binding sites of mRNA targets to repress
translation [5]. Here, using a combination of in vivo and in vitro
approaches, we have elucidated the function and the mechanism
of action of one of these sRNAs called RsaA [20]. We show that
RsaA, a Sigma B (sB)-dependent sRNA, represses the translation
of mgrA mRNA, which codes for a master regulator of
transcription [24–28]. Through MgrA regulation, RsaA activates
biofilm formation and inhibits capsule synthesis. Experimental
animal models showed that RsaA attenuates the severity of acute
systemic infections and enhances chronic catheter infection. These
data indicate that RsaA is part of a regulatory circuit that
contributes to the complex interactions of S. aureus with the
eukaryotic immune system.
Results
RsaA affects the synthesis of MgrA and of proteins
regulated by MgrA
To assess the function of RsaA, we first constructed an HG001-
derived strain, in which the rsaA gene was deleted and replaced by
aphA-3 (aminoglycoside 39-phosphotransferase, kanamycin resis-
tance). We have verified that RsaA expression in HG001, which is
sB-dependent, was maximal at the late-exponential phase of
growth and was abolished in the mutant DrsaA strain. In BHI
medium, growth was not affected by rsaA deletion. We then
analyzed the effect of the DrsaA mutation on protein synthesis
using comparative proteomics performed on cytosolic protein
extracts prepared from wild-type (HG001) and mutant DrsaA
strains grown in BHI medium to late-exponential growth phase.
Protein samples were pre-labeled with two different fluorescent
dyes (Cy3 and Cy5) and were separated by a two-dimensional
difference gel electrophoresis (DiGE). Even though only a small
proportion of cytosolic proteins (around 100 proteins) were
analyzed, we identified more than 10 proteins with significantly
altered expression patterns (Figures 1A, S1). Among the proteins
whose synthesis was significantly increased in the mutant strain,
was SpoVG, a protein involved in capsule synthesis [29]. Other
proteins involved in intermediary metabolism and in virulence
were also affected by the DrsaA mutation. Several of these proteins
belong to the regulon of the pleiotropic regulator MgrA [25,26]
but the effect of RsaA was opposite to that of MgrA.
RsaA contains an unpaired and conserved C-rich sequence,
suitable for interaction with ribosome binding sites (RBS) of
mRNAs, as previously shown for several other regulatory RNAs in
S. aureus [12–14,19–23]. Using IntaRNA [30] and targetRNA
[31], we searched for potential intermolecular base pairings
between the ribosome binding sites (RBS) of mRNAs (30
nucleotides (nts) downstream and 20 nts upstream of the AUG
codon) and the conserved unpaired region of RsaA. Interestingly,
the best mRNA candidate obtained by the two programs was mgrA
mRNA (Table S1). In addition, two mRNAs encoding SpoVG
and glycyl-tRNA synthetase, whose protein levels were decreased
in an RsaA-dependent fashion, were predicted to form base
pairings with RsaA (Figure 1B).
Because MgrA protein could not be detected by the differential
proteomic analysis, two alternative methods were used to analyze
whether the synthesis of MgrA was under the control of RsaA.
Protein extracts, prepared from the WT strain (HG001), the
DrsaA-HG001 mutant strain, and the same strain complemented
with a plasmid expressing RsaA under its own promoter were
analyzed by Western blot using monoclonal antibodies (generously
provided by A. Cheung) and by LC-MS-MS coupled to spectral
count analysis (Figure 1C, D). The data obtained by the two
methods were well correlated and showed that the yield of MgrA
protein was decreased by two-fold in the WT strain as compared
to the DrsaA mutant strain while the repression was even more
pronounced (about 10-fold) in the mutant strain expressing RsaA
from a plasmid. This effect was specific since the yield of the
ribosomal protein L21 remained identical in the various strains
(Figure 1C).
We have previously shown that S. aureus RNAIII, which
represses translation of target mRNAs, also affects their turnover.
Therefore, we analyzed the steady-state level of mgrA mRNA using
quantitative RT-PCR analysis on total RNA extracts prepared
from the WT (HG001 and Becker) strains, the DrsaA mutant
strains, and the same mutant strains transformed with a plasmid
expressing RsaA (Figure 1E). The data showed that the level of
mgrA mRNA was strongly enhanced in the DrsaA mutant strains
while complementation caused an even greater decrease in mRNA
yield than in the isogenic WT strains (Figure 1E). Because mgrA is
transcribed in two transcripts [27], which initiate at 2124 or 2
302 nts upstream of the initiation codon, northern experiments
were also performed (Figure 1F). The level of the longest mRNA
(from P2 promoter) decreased significantly at the late exponential
phase of growth in both the WT and DrsaA derivative of HG001,
indicating that the growth phase-dependent regulation of the P2
promoter is not under the control of RsaA (Figure 1F). Conversely,
the level of the second and smaller transcript (from P1 promoter)
was strongly enhanced in the mutant strain lacking the rsaA gene
(DrsaA). These data suggested that the mgrA mRNA transcribed
from the P1 promoter is under the control of RsaA while the
mRNA formed from the P2 promoter is regulated independently
of RsaA.
All in all, these data advocated that RsaA has a significant effect
on the S. aureus proteome most probably through indirect
interactions via the regulation of mgrA.
Author Summary
Staphylococcus aureus is a commensal and an opportunis-
tic pathogen that causes a large range of community and
hospital-acquired infections. The bacteria produce an array
of virulence factors, the expression of which is regulated
by a set of regulators including proteins and RNAs. In
recent years, a large number of small non-coding RNAs
encoded by the S. aureus genome have been identified
but determination of their function is still lagging behind.
This study shows that RsaA, a staphylococcal conserved
non-coding RNA, operates at the post-transcriptional level
by repressing the translation of the master regulatory
protein MgrA. The repression is based on a direct
interaction of RsaA with the ribosome binding site of
mgrA mRNA. Through MgrA regulation, RsaA activates
biofilm formation and inhibits capsule synthesis. Using
appropriate animal models, we showed that RsaA acts as a
suppressor of virulence because the deletion of its gene
increases the invasiveness of S. aureus in the mice sepsis
model. RsaA is thus part of complex regulatory network
that modify the interactions of S. aureus with the
eukaryotic immune system. These findings illustrate how
small RNAs can have a major impact in bacterial biology.
A Non-Coding RNA Modulates S. aureus Virulence
PLOS Pathogens | www.plospathogens.org 2 March 2014 | Volume 10 | Issue 3 | e1003979
RsaA binds to mgrA mRNA at two distinct regions
The predicted base pairing between RsaA (nts 65 to 108) and
mgrA mRNA (nts 228 to +16) suggested that the RsaA-dependent
repression of mgrA mRNA was governed by direct RsaA-mRNA
pairing. To map more precisely the regions of interaction, we
performed footprinting experiments using enzymatic and chemical
probing. The regions of interaction between mgrA mRNA and
RsaA were probed using RNase T1 (specific for unpaired
guanines), RNase T2 (specific for unpaired nucleotides with a
preference for adenines), RNase V1 and the endoribonuclease III
(specific for double stranded regions), and lead(II)-induced
cleavages (specific for unpaired nucleotides). We also used
Figure 1. RsaA regulates the synthesis of several metabolic enzymes. (A) 2-D fluorescence difference gel electrophoresis (DiGE) performed
on HG001 and DrsaA-HG001 strains reveals proteins whose synthesis is affected by the deletion of RsaA. The proteins were identified by mass
spectroscopy analysis. Ratios correspond to the quantification obtained for HG001 versus DrsaA strain (data from four independent experiments). In
the last column are given the proteins, which belong to the MgrA regulon as shown by Luong et al. [26]. Statistical differences (p,0.05, except for the
bifunctional GMP synthase : p,0.01) between the two strains were obtained for each protein. (B) Potential base pairings between RsaA and potential
mRNA targets are shown. The Shine and Dalgarno sequence (SD) of target mRNAs are shown in green while the conserved C rich motif in RsaA is in
red. Other predicted RsaA-mRNA complexes are shown in Table S1. (C) Relative MgrA protein expression level was defined by LC-MS-MS followed by
a spectral counting strategy. Protein extracts were prepared from HG001 (WT), DrsaA mutant strain, and the same strain complemented with a
plasmid expressing RsaA. In parallel to MgrA, we analyzed ribosomal protein L21 as internal control of constitutively expressed protein. The spectral
count was normalized to the value determined for the WT strain. (D) Western blot performed with monoclonal antibodies against MgrA performed
on protein extracts prepared from HG001, DrsaA mutant strain and the same strain complemented with a plasmid expressing RsaA. As a control, a gel
run in parallel with the same samples was stained with Coomassie blue to verify that each lane contained comparable amounts of protein. Protein
size markers were run in parallel. (E) The expression of RsaA and of mgrA mRNA was quantified and normalized to the level of gyrB mRNA expression
from total RNA extracts prepared from in vitro culture to the mid- or late-exponential phase of HG001 (WT), the DrsaA mutant strain, and the same
strain complemented with a plasmid expressing RsaA. (F) Northern experiments showing the steady state levels of mgrA mRNA in HG001 and in the
DrsaA mutant strains. Total RNAs were prepared after 2, 4 and 6 h of culture in BHI at 37uC. We used two different RNA probes to visualize the
expression of RsaA and of mgrA mRNA. We have previously shown that a longer transcript including RsaA was also expressed [20]. This longer form of
RsaA is known to be processed by RNase Y [37].
doi:10.1371/journal.ppat.1003979.g001
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dimethylsulfate, which methylates adenines at the N1 position and
cytosines at the N3 position to probe the structure of mgrA mRNA
and its interactions with RsaA. The cleavage sites were analyzed
using 59 end labeled RsaA while for mgrA mRNA, the cleavages
and chemical modifications were analyzed by primer extension
using reverse transcriptase. Experiments are shown in Figures 2A–
B.
The probing data obtained with RsaA alone correlated well
with the existence of three hairpin loops (Figure S2A) as previously
published [12–14,19–23]. Indeed, single-strand specific RNase
cleavages were mainly located in the apical loops and unpaired
regions while RNase V1 cuts were predominantly found in the
helices of RsaA. Furthermore, RNase III specifically cleaved helix
H1, in agreement with the observation that RsaA decay is
mediated by RNase III in vivo [23]. Enzymatic hydrolysis was then
performed on 59 end labeled RsaA incubated with increasing
concentrations of mgrA mRNA. Binding of mgrA mRNA affected
the cleavages at two distant regions of RsaA. Strong protections
were observed close to the C-rich motif of RsaA, i.e. at A83–85
against RNase T2, at U82-A94 against lead(II)-induced cleavages,
and at G86 against RNase T1 (Figure 2C). Concomitantly, several
enhanced RNase V1 cuts were found at U88-C89, and two strong
RNase III cleavages were observed at U82 and U87 of RsaA
(Figure 2A). Unexpectedly, binding of mgrA mRNA also induced
strong protections against single-strand specific probes in the
hairpin loop H1 at residues A27 to G33 of RsaA revealing the
existence of a second RNA binding site (Figure 2A, C).
The same experiments were performed on an mgrA fragment
encompassing 124 nts upstream of the initiation codon and
258 nts of the coding sequence (Figure 2B). The enzymatic
cleavages obtained on mgrA mRNA alone supported the existence
of the long hairpin IV within the coding sequence as well as the
stem-loop III structure, which partially sequestered the SD
sequence (Figure S1B). The guanines of the Shine and Dalgarno
(SD) sequence were indeed weakly accessible towards RNases T1
and T2. Binding of RsaA caused changes in the RNase cleavage
patterns at two distant regions of the mRNA, namely around the
RBS and in the hairpin loop IV located in the coding sequence
(Figure 2C). In particular, strong RNase V1 cleavages occurred at
positions C13 to A17, C70–C72 and C75, and two strong RNase
III cleavages were observed at A+1 and C-5 of mgrA mRNA
(Figure S2C). Concomitantly, RsaA-induced protections against
RNase T2 were observed in the hairpin loop IV (at A67, A68,
A74) and at nucleotide A-9 close to the SD sequence, and strong
Figure 2. Probing the structure of the inhibitory RsaA-mgrA mRNA complex using enzymes and lead(II)-induced cleavages. (A)
Reactions performed with 59-end-labeled RsaA alone (lane 3) or in the presence of an excess of mgrA mRNA (lane 4, 25 nM; lane 5, 50 nM; lane 6,
250 nM). Lanes 1, 2: incubation controls on free RNA or bound to mgrA mRNA, respectively. The experiments were performed with RNase V1 (V1),
lead(II) induced cleavages (Pb), Rnase T1 (T1), RNase T2 (T2) and the endoribonuclease III (RNase III). Lanes T, L: RNase T1 under denaturing conditions
and alkaline ladders, respectively. The two regions protected by mgrA are shown by bars. (B) Enzymatic reactions performed on mgrA mRNA alone
(lane 3) or bound to increasing concentrations of RsaA (lane 4, 25 nM; lane 5, 50 nM; lane 6, 250 nM). Same legend as in A. Lanes U, C, G, A: dideoxy-
sequencing reactions. (C) Structure of the RsaA-mgrA mRNA complex. Summary of the enzymatic cleavages on RsaA, mgrA, and the complex.
Enzymatic cleavages are given as follows: RNase T1 (black and plain arrow), RNase V1 (black and plain arrowhead), RNase T2 (arrow). Circled adenines
and cytosines in mgrA mRNA are reactive towards dimethylsulfate modification. The RNase III cleavages led to RNA fragments, which terminated by a
two-nucleotide 39 overhang. Reactivity changes induced by the binding of RsaA are indicated as follows: black circles denote strong protection,
enhancements and new RNase V1 cleavages are represented by asterisks. The mutations performed in RsaA and mgrA mRNA, are shown in the insert.
doi:10.1371/journal.ppat.1003979.g002
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reduction of reactivities of adenines at N1 against dimethylsulfate
were located at A+1, A-1, A-6, A-7 and A-9 in the RBS
(Figures 2B, 2C). Interestingly, the hairpin loop IV carries the
unpaired nucleotides UCGCUACU, which are fully complemen-
tary to the hairpin loop I of RsaA (AGUAGCGA) (Figure 2C).
All together, these data revealed that the mgrA mRNA-RsaA
complex is composed of a bipartite site, which implies the
formation of an imperfect duplex sequestering the RBS of mgrA
and a loop-loop interaction. Furthermore, the long imperfect
duplex creates a specific site for the RNase III.
RsaA inhibits ribosome binding in vitro and regulates
mgrA translation in vivo
Structure probing strongly suggested that RsaA would repress
translation initiation of mgrA. Toeprinting assays were first used to
monitor the effect of RsaA binding on the formation of the
initiation ribosomal complex involving the 30S ribosomal subunits,
the initiator tRNAMet, and mgrA mRNA. Formation of the ternary
complex, which blocked the elongation of a cDNA primer by
reverse transcriptase, produced a toeprint at A+16 (Figure 3A).
Binding of RsaA completely abolished the toeprint at a ratio of 1:1
(RsaA:mgrA mRNA). These data indicate that the RsaA-mgrA
mRNA complex is rapidly formed and sufficiently stable to
prevent the formation of the ribosomal initiation complex.
To further validate the in vivo relevance of RsaA-dependent
repression of mgrA mRNA, we analyzed the expression of a
reporter construct in S. aureus HG001-DrsaA strain expressing the
wild-type (WT) RsaA. Mutations were introduced in both mgrA
and RsaA at the two binding sites (S1 and S2), and were designed
to disrupt or restore base pairings (Figure 2C). The entire leader
regulatory region of the mgrA gene produced from P1 (124 nts
upstream of the initiation codon) including 258 nts of the coding
sequence was cloned in-frame with the lacZ gene into the pTCV-
lac shuttle vector (Table S2). This construct is under the control of
a constitutive promoter (PrpoB). ß-galactosidase activity assays
were first performed in the S. aureus DrsaA mutant strain
transformed with the pCN38 vector expressing WT RsaA from
its own promoter. The ß-galactosidase activity was 4-fold lower in
the DrsaA mutant strain expressing WT RsaA than in the same
strain transformed with the control vector (Figure 3B). To probe
the importance of the first binding site, we introduced mutations in
the stem-loop structure H2 of RsaA where 86GUUCU90 was
substituted by CAAGA (RsaA-S1) to weaken the interaction with
the RBS of mgrA mRNA (Figure 2C). The ß-galactosidase activity
was reproducibly enhanced 3-fold in the DrsaA mutant strain
expressing RsaA-S1 as compared to the DrsaA strain expressing
WT RsaA (Figure 3B). Thus, disruption of the predicted base
pairings alleviated the repression of the reporter mgrA-WT-lacZ
gene. We then introduced changes in the RBS of mgrA-lacZ
reporter gene where -9AGAAC-5 was replaced by UCUUG to
restore base pairing with RsaA-S1. This mutation weakened the
strength of the SD-aSD helix since the first adenine of the SD
sequence was substituted by a guanine. Indeed, the resulting
mutated mgrA-S1-lacZ fusion produced less ß-galactosidase than
the WT fusion (Figure 3B). The expression of WT RsaA reduced
only slightly the ß-galactosidase synthesis while RsaA-S1 caused a
significant reduction of the ß-galactosidase synthesis from the
fusion mgrA-S1-lacZ by a reproducible 4-fold factor (Figure 3B).
Figure 3. RsaA-dependent repression of mgrA mRNA translation. (A) Effect of RsaA on the formation of the initiation ribosomal complex.
Lane 1: incubation control of mgrA mRNA; lane 2: formation of the initiation ribosomal complex containing mgrA mRNA, the initiator tRNA, and the
30S subunits; lane 3: incubation control of mgrA mRNA bound to RsaA; lanes 4 to 8: formation of the initiation ribosomal complex in the presence of
increasing concentrations of RsaA: 20, 50, 150, 500 nM and 1 mM, respectively; lanes C, U, A: sequencing ladders. (B) ß-galactosidase activity detected
from different gene fusions. ß-galactosidase activity was measured from PrpoB-mgrA (+1/+258)::lacZ fusion or from PrpoB-mgrA-S1 (+1/+258)::lacZ
fusion expressed in HG001-DrsaA strain. The experiments were carried out in DrsaA-HG001 mutant strain transformed with the plasmid pCN38
containing no insert (pCN38) or expressing the WT RsaA, or its two mutant derivatives RsaA-S1 (85GUUCU89 changed to CAAGA) and RsaA-S2
(28GUAGCG33 changed to CAUCGC). The ß-galactosidase activity was normalized for total cell density and is represented as a percentage of the
uninhibited control. The results represented a mean of four independent experiments. Statistical differences * (p,0.05) and ** (p,0.005) between
each construct were obtained by using Anova test.
doi:10.1371/journal.ppat.1003979.g003
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The contribution of the second binding site in regulation was also
analyzed. Mutations were introduced in the hairpin loop H1 of
RsaA (RsaA-S2, 28GUAGCG33 changed to CAUCGC) to
destabilize the loop-loop interaction. The data showed that the
ß-galactosidase synthesis obtained from mgrA-WT-lacZ was
strongly enhanced in the DrsaA strain expressing RsaA-S2 as
compared to the same strain expressing the WT RsaA. Hence,
disruption of the loop-loop interaction significantly alleviated
repression of mgrA (Figure 3B).
Taken together, these data showed that RsaA represses the
synthesis of MgrA at the post-transcriptional level through the
formation of an RsaA-mRNA duplex, which sequesters the RBS of
mgrA mRNA. Furthermore, the two distant regions of interaction
contribute to the repression of MgrA synthesis.
The two binding sites are essential for RsaA-dependent
translation inhibition of mgrA
The effects of mutations that disrupt or restore base pairings
were further analyzed for their ability to form RNA-RNA
interactions and their ability to inhibit mgrA translation. The
formation of the RsaA-mRNA complex was followed using gel
retardation assays (Figure 4B). In vitro 59 end-labeled RsaA was
incubated with increasing concentrations of mgrA mRNA. This
experiment showed that mgrA mRNA binds to RsaA with a Kd
value of around 20 nM. The initial rate of RsaA binding was
estimated from a time-course analysis and resulted in an
association rate constant of 56105 M21s21 indicating that the
complex is rapidly formed. Mutations of the RBS of mgrA (mgrA-
S1) had a strong effect on binding to WT RsaA while
compensatory mutations performed in RsaA-S1 restored the
binding albeit with less efficiency (Kd value around 50 nM).
Disruption of the loop-loop interaction caused a strong effect on
the binding of mgrA-S2 to WT RsaA (Figure 4B). Therefore, both
regions of interaction contribute to the stability of the RsaA-
mRNA complex indicating that they act in a cooperative manner.
We then performed in vitro translation assays (PUREsystem) using
the whole mgrA mRNA (expressed either from the P1 or the P2
promoter) carrying the sequence encoding a FLAG tag to visualize
the protein by Western blot using FLAG-specific monoclonal
antibodies. Addition of WT RsaA specifically repressed the
translation of both mgrA mRNAs (Figure 4C). These data were
well correlated with the in vivo reporter assays (Figure 3B). The same
experiment was performed with mutated versions of mgrA mRNA
(mgrA-S1, mgrA-S2) expressed from the P1 promoter. Consistent
with the binding experiments, the addition of WT RsaA had no
effect on the translation of mgrA-S1 while RsaA-S1 efficiently
inhibited the translation of mgrA-S1 (Figure 4C). Furthermore,
destabilization of the loop-loop interaction had a significant effect
on translation repression because higher concentrations of WT
RsaA were required to achieve inhibition with mgrA-S2 compared to
WT mgrA (Figure 4C).
All in all, these data show that RsaA inhibits initiation of
translation of mgrA and that the two regions of interaction
contribute to binding and regulation.
Deletion of RsaA reduces biofilm formation
We then analyzed whether RsaA is able to counteract the action
of the master regulator of transcription MgrA. The effect of RsaA
Figure 4. Contribution of the two binding sites of RsaA-mgrA duplex on translation repression. (A) Schematic drawings showing the two
sites of interaction in the RsaA-mgrA complex. The various mutations are indicated. (B) Gel retardation assays to follow the formation of RsaA-mgrA
complex. The 59 end-labeled wild-type (WT) RsaA or the mutant RsaA-S2 were incubated with increasing concentrations of either the WT mgrA mRNA
or its two mutant derivatives (mgrA-S1, mgrA-S2): lane 2, 5 nM; lane 3, 10 nM; lane 4, 20 nM; lane 5, 50 nM; lane 6, 100 nM; lane 7, 500 nM. Lane 1:
free 59 end-labeled RsaA. The bands corresponding to the free RsaA and to the complexes are specified. (C) In vitro translation assays using the
PURESYSTEM. The reactions were performed with 10 pmol of WT mgrA or its two mutant derivatives (mgrA-S1, mgrA-S2) alone (lane 1) or in the
presence of increasing quantities of WT RsaA or RsaA-S1 (lane 2: 5, lane 3: 10, lane 4: 30 and lane 5: 50 pmoles). The two mRNAs produced from the
P1 or the P2 promoter were also analyzed. The same experiment was performed with YFP protein as the negative control. The proteins were
separated on a SDS-PAGE 10% and were revealed using FLAG-specific antibodies.
doi:10.1371/journal.ppat.1003979.g004
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was monitored on biofilm and capsule formation, which are two
processes known to be regulated by MgrA [24,26,32,33].
The biofilm Ring Test was used to follow the kinetics of early
biofilm formation. This approach focuses on adhesion and
aggregation of bacteria to a substrate (Figure 5A). We analyzed
various strain backgrounds, namely RN6390 (sB2), HG001 (sB+),
Newman and Becker (clinical isolates, sB+) as well as their rsaA
mutant and complemented counterparts. For all genetic back-
grounds, the rsaA inactivation induced a delay in the kinetic of
biofilm formation but this delay was variable according to the
genetic background (Figure 5A). The delay in the kinetics of early
biofilm formation of mutant vs WT strains was equal to 10 min for
RN6390, 30 min for HG001, 1 h 30 for Becker and 2 h 10 for
Newman. The rsaA complementation restored fully (RN6390 and
HG001) or partially (Becker and Newman) the parental pheno-
type. The Becker DmgrA strain, generously provided by C. Lee,
was used as a control. As expected [32], the inactivation of mgrA
reduced the delay of early biofilm formation by about 1 h 30 in
comparison to the WT strain. The double mutant DmgrA-DrsaA
Becker strain did not further reduce the delay of biofilm formation,
supporting that RsaA regulated the biofilm formation via mgrA
inhibition. Of note, RsaA plasmid complementation of the DmgrA-
DrsaA Becker strain did not change the biofilm phenotype
obtained with the double mutant.
Quantification of mature biofilm after 24 h was also performed
for all strains (Figure 5B). The level of mature biofilm was
extremely abundant for HG001, intermediate for Becker and
RN6390, and moderate for Newman. The inactivation of rsaA was
associated with a significant decrease in biofilm thickness in the
three strain backgrounds. Conversely, the plasmid complementa-
tion restored the parental WT phenotype and biofilm formation
was even slightly higher due to the overexpression of RsaA. As a
negative control, transformation with the empty plasmid showed
no effect (Figure 5B). Furthermore, mgrA inactivation in the Becker
strain induced a high increase in mature biofilm formation, as
previously published [32]. As expected, the double mutant DrsaA-
DmgrA Becker strain, and the same strain complemented with a
plasmid expressing RsaA, produced a phenotype similar to that of
the single DmgrA Becker strain.
The icaADBC operon encoding the extracellular polysaccharide
adhesin PIA/PNAG (polysaccharide intracellular adhesion/poly-
N-acetylglucosamine) is responsible for some of the biofilm-
positive phenotypes in S. aureus [34]. However, S. aureus can
produce an alternative ica-independent biofilm via the expression
of mgrA [32]. To rule out an involvement of icaADBC in the RsaA-
dependent biofilm formation, we quantified PIA/PNAG produc-
tion using an anti-PIA/PNAG specific antibody in the three strain
backgrounds. We saw that the inactivation of rsaA had no effect on
PIA/PNAG production for the equivalent quantity of bacterial
lysates (Figure S3).
In summary, these data suggested that RsaA is acting upstream
of MgrA and activates biofilm formation through the inhibition of
MgrA synthesis.
RsaA inhibits capsule production and prevents
opsonization of S. aureus
To study whether RsaA was involved in capsule regulation, we
quantified capsule production after an overnight culture using
anti-CP5 or anti-CP8 specific antibodies. Using equivalent
amounts of bacterial lysates, we found that the Becker strain
(capsular polysaccharide type 8, CP8) produced more capsular
polysaccharides than Newman and HG001 (capsular polysaccha-
ride type 5, CP5). The inactivation of rsaA induced a significant
increase in CP8 biosynthesis in the Becker strain and in CP5 in the
Newman strain while only a slight increase in CP5 was detectable
for HG001 (Figure 6A). The expression of RsaA from a plasmid
restored the parental WT phenotype for all strains. The same
results were obtained after 6, 9 and 12 h of culture (data not
shown). To verify that the regulation of capsule production by
RsaA resulted from mgrA repression, we again analyzed the
phenotype of the double mutant DrsaA-DmgrA in the Becker strain
background. Compared to the WT, the level of CP8 production
was considerably reduced in the single DmgrA mutant strain as well
as in the double mutant DrsaA-DmgrA strain. Noticeably, we
reproducibly found that the complementation of the double
mutant with a plasmid expressing RsaA further reduced the level
of CP8 production, suggesting the existence of an mgrA-indepen-
dent repression effect of capsule production. This additional effect
might be attributed to the RsaA-dependent inhibition of SpoVG
(Figures 1, S1), a protein involved in the capsule formation [29].
To illustrate the accumulation of capsular polysaccharides in
DrsaA mutant strains, indirect fluorescence was performed to
investigate the capsule formation of the Becker strain and its
derivatives after 7 h of growth in BHI. Strikingly, the capsule was
highly labeled only in the DrsaA mutant Becker strain contrasting
with the WT parental and complemented strains (Figure 6B). To
verify the specificity of the secondary antibody, the same
experiment was performed without the primary CP8 antibody,
and as expected, all strains were only labeled in green (data not
shown).
Because capsular polysaccharides protect S. aureus against
opsonophagocytic killing by polymorphonuclear leukocytes
(PMNs) [35,36], we measured the percentage of bacteria killed
after contact with serum and PMNs in strains expressing or deleted
for RsaA. The data were not statistically significant because a large
variability of bacterial survival was observed due to inter-PMNs
donor differences. However, in the mutant strains, fewer bacteria
were killed than in the parental strains expressing RsaA
(particularly in the Becker strain background) in each replicate
(Figure S4).
These data showed that RsaA significantly represses capsule
synthesis in all strain backgrounds and renders S. aureus more
sensitive to opsonophagocytic killing by PMNs.
RsaA attenuates virulence in mice infectious models
Because RsaA impacts both biofilm and capsular formation, we
selected two animal models in mice that were considered relevant
with respect to these processes, namely, the catheter infection
model (for biofilm) and the intraperitoneal infection model (for the
capsule).
For the in vivo catheter infection model, sections of polyurethane
catheter (1 cm) were implanted sub-cutaneously into C57BL/6
mice and filled with about 46104 bacteria/25 ml (Becker WT and
DrsaA mutant strains) in PBS (6 mice/group). The catheters were
implanted for 3, 6 or 10 days. No difference in weight was
observed between the mice infected by the WT and mutant strains
(data not shown). Both strains led to a local infection with swelling
but the size of the swelling was not significantly different between
the studied strains (data not shown). At day 3, the concentration of
colony-forming units observed on the catheters was significantly
higher in mice infected with the WT strain than those infected by
the DrsaA mutant strain (p = 0.0173) (Figure 7A). Between days 6
and 10, this difference was no longer observed in mice infected
with WT and mutant strains, likely due to the saturation of the
growth within the catheters (Figure 7A). However, between days 3,
6 and 10, more colony-forming units were observed in the
surrounding tissues of the mice infected with the WT strain while
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Figure 5. Effect of RsaA on biofilm formation. (A) Kinetics of the early phase of biofilm formation in different S. aureus backgrounds with the
Biofilm Ring Test at different incubation times. Standardized bacterial cultures were incubated in 96 well micro-titer plate in the presence of magnetic
beads at 37uC. A plate reader measures the number of beads in each well before and after magnetization. The beads are gathered in the center of the
well if no biofilm is formed whereas the beads are dispersed if they are immobilized into the biofilm. The Biofilm Forming Index (BFI) corresponds to
the mobility of beads under magnet action. Results are expressed as the DBFI corresponding to the difference between a control well (without
bacteria) and the studied sample. A value of DBFI.7 means that the biofilm is formed. Data obtained for each strain were shown with a color code as
given in the figure: blue for the parental wild-type (RN6390, Newman, Becker) strains, red for the DrsaA mutant strain, and green for the
complemented strain expressing RsaA from a plasmid. (B) Analysis of the mature biofilm formation with crystal violet staining. Overnight bacterial
cultures were standardized and incubated 24 h at 37uC in rich medium supplemented with glucose 0.25%. The mature biofilm was stained by crystal
violet 0.1%, released with acetic acid 33%, and quantified by OD570 nm. The mean and the standard deviations are presented on the histogram.
Statistical differences * (p,0.05) and ** (p,0.005) between each strains were obtained by using Anova test.
doi:10.1371/journal.ppat.1003979.g005
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the number of colony-forming units of the mutant DrsaA strain
remained unchanged (Figure 7B).
For the bacteremia model, we included the two major capsular
types of S. aureus (type 5 and 8), namely Newman (type 5) and
Becker (type 8), their DrsaA mutant derivatives, as well as their
complemented counterparts (studied at the early time point only).
Mice were challenged with sub-lethal doses of each strain by intra-
peritoneal injection (16106 bacteria/500 ml). Animals challenged
Figure 6. Effect of RsaA on capsule formation. (A) Dot-blot analysis of capsular polysaccharide accumulation in wild-type strains and its
corresponding DrsaA mutant and complemented strains after growth in BHI for 16 h. Standardized bacterial suspensions were treated with
lysostaphine, DNase I and proteinase K, and 1/3 serial dilutions were spotted onto nitrocellulose membranes. Capsular polysaccharides were detected
with an anti-CP5 (HG001 and Newman) or CP8 (Becker) antisera. The DrsaA mutant produced a higher level of capsular polysaccharides and the
DmgrA mutant produced a lower level of capsular polysaccharides. The inactivation of both rsaA and mgrA revealed that the repression of capsule
production by rsaA achieved via the repression of mgrA. (B) Capsule production in Becker strain and its derivatives grown for 7 h in BHI at 37uC. CP8
expression was determined by indirect immunofluorescence of WT strain, the DrsaA mutant strain (LUG2010) and the mutant strain complemented
with a plasmid expressing RsaA (LUG2032). The bacteria were labeled with Bodipy-vancomycine and capsule was labeled with an anti-CP8 antibody
and a rabbit anti-IgG coupled with a fluorochrome AlexaFluor 647.
doi:10.1371/journal.ppat.1003979.g006
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with the strongly encapsulated strains (Becker-DrsaA) showed a
significantly (p,0.005) higher bacteremia level at 1 h and 3 h after
inoculation compared with animals infected with the parental and
complemented strains (both less encapsulated) (Figures 7C and
S5A). Furthermore, after 1 h and 3 h, the blood concentrations of
DrsaA bacteria were significantly higher (p,0.05) than those of
parental and complemented strains (Figures 7D and S5B). The
same results were obtained with Newman background (Figures
S5C–F). Evolution of the infection was followed by collecting the
mice spleen for bacterial numeration. After 1 and 2 days, the
bacterial counts in the spleen were generally higher in the DrsaA
mutant strain- vs WT strain-infected animals for both Becker
(Figure S5H) and Newman (Figure S5G) backgrounds. However,
this difference only reached significance in the spleen after 1 day
with Newman strain and after 2 days with Becker strain.
Our data obtained with both animal models suggested that
RsaA diminishes invasiveness but favors chronic infections and
local colonization.
RsaA is expressed by clinical isolates of S. aureus
The observation that RsaA impacted oppositely biofilm
formation and invasiveness raised the question as to whether
Figure 7. The impact of RsaA on virulence in in vivo animal models. Two in vivo infections models were developed: a catheter infection
model (to mimic a chronic infection) and a bacteremia model (to mimic an acute infection). Quantification of bacteria into catheter (A) and in the
surrounding tissues (B) after 3, 6 and 10 days post-infection. After euthanasia of mice, the catheters and surrounding tissues were removed and
processed as described in Materials and Methods. Bacteria were enumerated by serial dilution and plate counting on agar plates. The results were
expressed in number of CFU/ml. Each point designates the number of bacteria for each mouse and the black line represents the mean of each tested
condition. The second model was performed by intraoperitonnal (IP) injection of 16106 bacteria. At 3 h post-infection, viable bacteria present into IP
(C) and in blood (D) were enumerated by serial dilution and plate counting on agar plates. The results were expressed in number of CFU/ml.
Statistical differences * (p,0.05) and ** (p,0.005) between each groups were obtained by using Mann Whitney test.
doi:10.1371/journal.ppat.1003979.g007
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clinical isolates would express differential levels of RsaA depending
on the clinical situation in which they had been sampled. To this
end, a series of 18 isolates reflecting the commensal status of S.
aureus (nasal colonization) as well as S. aureus diseases in various
forms (chronic lung infection in cystic fibrosis patients, non-
invasive acute skin and soft tissue infections, severe invasive disease
illustrated by community-acquired pneumonia and infective
endocarditis), were tested for RsaA expression at mid and late-
exponential phases by RT-qPCR. The results revealed no specific
correlation between RsaA expression levels and invasiveness, both
at the mid and late-exponential state of growth (Figure S6A). Of
note, all reference strains tested (HG001, Becker, Newman,
USA300 LAC and SF8300, and the European CA-MRSA ST80)
showed equivalent levels of RsaA production (Figure S6B).
Discussion
RsaA regulates the synthesis of the master global
regulator MgrA
The virulence of S. aureus is in part conferred by numerous
effector proteins that interact with the host. The levels of these
virulence factors are controlled by a set of more than 20
transcriptional regulatory proteins [2]. However, S. aureus strains
are genetically highly diverse and it is well recognized that their
regulatory networks are not uniform. In order to determine the
virulence traits of a defined strain, we must understand how the
regulators interact with each other and how novel regulators such
as non-coding RNAs influence these networks.
In this work, we show that the small non-coding RNA RsaA
functionally links two global regulators, the sB and MgrA proteins.
The transcription of RsaA was shown to be under the control of
sB protein [20], while its fate was determined by two
endoribonucleases, the double-strand specific RNase III [23] and
RNase Y [37]. Our data indicate that the mgrA mRNA is repressed
at the stationary phase of growth in an RsaA-dependent and
RsaA-independent manner. The mgrA mRNA is transcribed from
two promoters, and the mRNA with a longer 59UTR was no
longer produced at the late-exponential phase when RsaA was
produced (Figure 1F). Whether the regulation is mediated by a
protein- or another sRNA remains to be studied. Using a
combination of approaches in vivo and in vitro, we showed that
the primary effect of RsaA is to repress the translation of mgrA
mRNA by preventing the formation of the ribosomal initiation
complex. The steady state level of the mRNA was also
substantially enhanced in the DrsaA strain suggesting subsequent
degradation of the repressed mRNA. A reduction of mgrA mRNA
from the P1 promoter was also observed at the post-exponential
phase of growth in various sB+ strains, and the levels of mgrA
mRNA were found to be higher in RN6390 (sB2) than in SH1000
(sB+) [38]. This was correlated in vivo with the level of MgrA
protein, which was found to be higher in the DrsaA mutant strain
than in the isogenic WT strain (Figures 1C, D). In vitro binding
assays showed that RsaA binds to mgrA mRNA with a fast
association rate constant, which is essential for efficient repression
because the sRNA has to bind to its target mRNA within a short
time frame before the stable ribosomal initiation complex is
formed [39]. Two stretches of highly conserved and unpaired
nucleotides of RsaA bind to two distant regions of mgrA, a C-rich
motif of RsaA masks the SD sequence of mgrA while a loop-loop
interaction occurs between two hairpin loop structures found in
the 59 end of RsaA and in the coding sequence of mgrA (Figure 8A).
Mutational analysis revealed that the two RsaA binding sites are
required for optimal binding and mgrA translation repression in vivo
(Figures 3 and 4).
It is worth noting that RsaA and RNAIII share very similar
regulatory mechanisms [11,40] suggesting that the importance of
bi-partite RNA-RNA binding sites in translation repression
appears to be more general than previously expected in S. aureus
(Figure 8A). In both cases, their mRNA targets are characterized
by two regulatory modules: the SD sequence interacts with a C-
rich motif within the regulatory RNAs to prevent ribosome
binding and to create a specific RNase III binding site, while a
hairpin motif constitutes either a second RNA binding site to
stabilize the RNA-RNA interaction or to promote a specific
binding site for RNase III [5,10]. For the RsaA-mgrA complex, the
second interaction site involves a loop-loop interaction, which
greatly enhances the stability of the complex and the efficiency of
translation repression (Figure 4). RNase III-dependent cleavages
were observed at the site of interaction formed between the RBS of
mgrA and the C-rich motif of RsaA. Note that mgrA mRNA and
RsaA were co-immunoprecipitated with RNase III and the half-
life of RsaA was significantly enhanced in the Drnc mutant strain
[23]. As it was shown for RNAIII, it is tempting to propose that
RNase III also contributes to the degradation of the translationally
repressed mgrA mRNA. In addition, since MgrA positively
autoregulates its own transcription [27], RsaA-dependent repres-
sion of mgrA translation might indirectly inhibit mgrA transcription.
RsaA-dependent regulatory circuit might be linked to the
quorum sensing system
By regulating the translation of MgrA, RsaA participates in a
complex regulatory network involving two global regulators, which
modulate the levels of RNAIII, thus affecting biofilm formation
and capsule synthesis (Figure 8). RsaA expression is positively
regulated by the alternative sB factor [20], an observation that is
well correlated with our data. Indeed, rsaA inactivation affected
less strongly the kinetics of biofilm development in RN6390 (sB2,
10 min) than in HG001 (sB+, 30 min) due to the fact that the
sRNA was not strongly expressed in RN6390 [20]. RsaA synthesis
follows the same pattern as sB, which is activated at a basal level at
the exponential phase and strongly enhanced at the stationary
phase [41]. Furthermore, sB affected the transcription of the
virulence genes in an opposite manner to RNAIII, and this effect
would be in part the consequence of lower RNAIII levels in strains
harbouring a fully active sB [41]. sB was also shown to enhance
resistance to oxidative and UV stresses, biofilm, and capsule
formation. The sB-dependent activation of biofilm formation
occurs via the icaADBC operon [42,43]. We show that RsaA does
not perturb the production of the PIA/PNAG polysaccharides
produced by the icaADBC operon (Figure S2), but affects
pathways that are predominantly dependent on mgrA. sB is also
known to activate the capsule synthesis via the two-component
system ArlRS and yabJ-spoVG [33]. It is worth noting that yabJ-
spoVG is a potential mRNA target of RsaA whose expression was
altered in the proteome analysis, and for which base pairings with
RsaA have been predicted (Figure 1). The main target of RsaA,
which is the transcription factor MgrA, regulates more than 350
genes [26]. MgrA is activated by the arlRS operon, whose
expression is controlled by sB [26]. Taken together, the expression
of MgrA is under the control of an incoherent feed-forward loop,
involving a positive loop mediated through ArlRS and a negative
loop mediated through RsaA (Figure 8). In addition, a recent study
revealed that the DNA binding activity of MgrA is modulated
through specific phosphorylation by the eukaryotic like kinase
phosphatase pair Stk1-Stp1 [44]. Hence, the expression of this
master regulator is controlled through multiple pathways. MgrA is
central to the regulation of biofilm and represses the production of
two out of the three components of the biofilm, i.e. surface proteins
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and exogenous DNA release [32]. Indeed, MgrA negatively
regulates the DNA release by suppressing cidA expression and
activating lrgAB encoding a peptidoglycan hydrolase and an
inhibitor of murein hydrolase activity, respectively [32]. Through
its synergistic action on these two loci, MgrA inhibits cell autolysis
and the release of DNA within the biofilm [32]. The second
control exerted by MgrA is to activate the agr system, in a quorum
sensing-independent pathway, to inhibit the synthesis of surface
proteins essential for adhesion [25,26]. Although mgrA mutations
significantly reduced RNAIII levels [25,27], the protein also
bypasses the quorum sensing system by directly activating the hla
gene and repressing spa gene expression via sarS. As with the agr
system, MgrA also has a positive effect on capsule synthesis [26],
and in a rat infective endocarditis model, MgrA was shown to be
the major regulator of capsule formation in vivo [28]. In correlation
with these studies, we showed that inactivation of rsaA alleviates
the repression of mgrA to increase capsule synthesis (Figure 6).
Therefore, we propose that RsaA functionally links the global
regulators sB and mgrA, with potential consequences on the
temporal expression of virulence determinants ([25,26]; Figure 8).
We demonstrate that RsaA activates biofilm formation (Figure 5)
and represses capsule synthesis (Figure 6) most probably via the
repression of mgrA translation. The regulation of these two
phenotypes has been extensively studied in pathogenic bacteria
demonstrating a complex interdependency. Studies in Staphylococ-
cus haemolyticus and Streptococcus pneumoniae highlighted that encap-
sulated strains produced little or no biofilm, whereas non-
capsulated strains produced a strong biofilm [45]. Moreover,
inactivation of the cap operon of S. haemolyticus JCS1435 (sharing
57% of sequence similarity with S. aureus cap) induced biofilm
formation [46] suggesting that the capsule would partially mask or
inhibit the surface proteins essential for biofilm formation. In our
Figure 8. RsaA and its regulatory circuits. (A) Schematic drawing summarizing the regulatory mechanism. RsaA binds to mgrA mRNA and
inhibits translation by preventing the 30S subunit binding, and recruits RNase III to induce simultaneous degradation of both RNAs. (B) RsaA is
activated by sB and in turn represses mgrA translation. RsaA is thus indirectly linked to RNAIII regulatory networks because MgrA activates agrACDB
expression while sB represses it [32,41]. Arrows are for activation, bars for repression. In blue are the transcriptional protein regulators, in red the
regulatory RNAs and in grey the virulence factors. Red lines corresponded to post-transcriptional regulation and black lines to transcriptional
regulation. The regulatory events for which direct regulation is not yet demonstrated are shown by dotted lines.
doi:10.1371/journal.ppat.1003979.g008
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study, we demonstrated this imbalance in favour of biofilm
production for the HG001 strain that is minimally encapsulated
but produces lots of biofilm; or in favour of the capsule synthesis
for Becker and Newman strains that produce small amounts of
biofilm but abundant capsule (Figures 5 and 6). The mechanistic
details of this imbalance are not totally understood and may
certainly involve other factors besides MgrA and RsaA.
RsaA favors chronic infection and attenuates
invasiveness
The pathogenic bacterial chromosome is composed of the core
genome plus accessory elements. The accessory genome contains
genes that have been horizontally acquired through mobile genetic
elements (plasmids, phages, pathogenicity islands). The acquisition
of these elements, which often encode virulence determinants and
antibiotic resistance, has been accompanied by subsequent
adaptation of the bacteria to successfully incorporate these novel
elements [47]. Some pathogenic bacteria harbour genes that can
hinder the expression of acquired virulence factors, and certain
genes must be inactivated for the expression of full pathogenicity
[48]. Other bacterial genes lead to hypervirulence when they are
inactivated [49]. This family of genes was identified in several
pathogenic bacteria such as Listeria monocytogenes [50] or Salmonella
enterica [51]. For instance, in S. enterica the leucin-responsive
regulatory protein (Lrp) represses key virulence factors involved in
the invasion of host cells [51]. These genes encode proteins, but
recently an antisense RNA in S. typhimurium was shown to
kinetically control the virulence determinant MgtC, which is
required for defense against the host immune system [52].
Deletion of this antisense RNA causes an hypervirulent phenotype.
In the present study, we demonstrate that RsaA, a non-essential
ncRNA present in all Staphylococcus species [20] reduces the
virulence of S. aureus. Indeed, the deletion of rsaA increases the
invasiveness of the bacteria in the mice sepsis model and resistance
to opsonophagocytic killing. Conversely, RsaA promotes biofilm
formation and catheter colonization in mice, potentially promot-
ing harmful colonization and chronic infections in human.
Noticeably, quantification of RsaA expression from human clinical
isolates revealed that Rsa is functional in all clinical isolates of S.
aureus studied so far [53] but is not differentially expressed
depending on the level of invasiveness ranging from commensal-
ism to deep-seated infections (Figure S6). Of note, we also showed
previously by direct quantification from clinical samples that RsaA
is expressed in all clinical samples including nasal secretion [53].
Since Staphylococci are mainly present as commensal bacteria of
warm-blooded organisms (e.g. mammals and birds), the function-
ality of RsaA as a suppressor of virulence may have been positively
selected through evolution because it is favorable for commensal-
ism and saprophytic interactions with the host. We thus postulate
that mutations leading to RsaA deficiency would be counter
selective, perhaps because hypervirulence would be deleterious to
the human host that is the natural reservoir of this bacterium.
Materials and Methods
Ethics statement
All mouse protocols were carried out in strict accordance with
the Directive 2010/63/EU revising Directive 86/609/EEC on the
protection of animals used for scientific purposes. This directive
was translated in the French regulation as the De´creˆt nu2013-118
of Feb 2013 under the jurisdiction of the Ministry of Education,
Research and Technology. The protocols were approved by the
CECCAPP (Comite´ d’Evaluation Commun au Centre Le´on Be´rard, a`
l’Animalerie de transit de l’ENS, au PBES et au laboratoire P4) under
identification numbers ENS_2011_033 and ENS_2012_051 for
biofilm and bacteremia models, respectively.
Strains, plasmids and growth conditions
The Staphylococcus aureus strains, clinical isolates, and plasmids
used in this study are listed in Table S2. Escherichia coli strain DH5a
(Promega, Madison, USA) was used as a host strain for plasmid
constructions. S. aureus strain RN4220 [54] was used as the
recipient in electroporation of the constructed plasmids. Staphylo-
cocci were grown either on GP agar plates (1% peptone, 0,5% yeast
extract, 0,5% NaCl, 0,1% glucose, 1,7% agar, pH 7,2) or in brain-
heart infusion (BHI) supplemented with erythromycin (5 mg/ml) or
chloramphenicol (10 mg/ml) when appropriate. E. coli strains were
cultivated in Luria-Bertani medium (1% peptone, 0,5% yeast
extract, 1% NaCl). Total DNA and plasmid DNA were prepared
using DNAeasy tissue Kit Qiagen and Qiaprep Miniprep
respectively (Qiagen, Valencia, USA). Transformation of E. coli
DH5a was performed by thermic shock and S. aureus strains were
transformed by electroporation (Bio-Rad gene Pulser).
The deletions/replacements DrsaA/aphA-3 mutants of S. aureus
RN6390 (LUG1450), HG001 (LUG1630), Newman (LUG1680),
Becker (LUG2010) and CYL1040 (LUG2009) strains were
obtained using pMAD [55]. The kanamycin resistance gene
aphA-3 was cloned in pMAD between two DNA fragments
corresponding to the chromosomal regions upstream and down-
stream of the rsaA coding sequence using primers rsaA-76/rsaA-
1120 and rsaA-1246/rsaA-2194, respectively (Table S3). The
resulting plasmid (pLUG754) was electroporated into RN4220
recipient strain and then transferred to RN6390, HG001,
Newman, Becker and CYL1040. Growth at non-permissive
temperature (44uC) was followed by several subcultures at 30uC
and 37uC to favor double crossing over as previously described
[10]. To complement these mutant strains, the rsaA gene was
amplified using rsaA-76/rsaA-2194 oligonucleotides and inserted
into pLUG274 forming pLUG959. Complementation of mutant
strains was performed using pE194, pCN51 or pCN38 carrying
rsaA gene (Table S2). The CYL1040 was generously provided by
CY Lee [24].
Preparation of RNAs
PCR fragments containing RsaA and its derivatives (RsaA-S1,
RsaA-S2) were cloned into pUC18 vector, and then were
transcribed in vitro using T7 RNA polymerase after plasmid
linearization. The WT mgrA mRNA (2124 to +258) and its
derivative (mgrA-S1, mgrA-S2) fragments were transcribed from
PCR fragments (Table S3). The transcribed RNAs were purified
by 8% polyacrylamide-8 M urea gel electrophoresis. After elution
in 0.5 M ammonium acetate/1 mM EDTA buffer, the RNAs
were precipitated twice with ethanol. The 59 end-labeling of
dephosphorylated RNA or DNA oligonucleotides was performed
with T4 polynucleotide kinase and [c-32P]ATP. Before use, RNAs
were renatured by incubation at 90uC for 2 min in the absence of
magnesium and salt, 1 min on ice, followed by an incubation step
at 37uC for 15 min in TMN buffer (20 mM Tris-acetate pH 7.5,
10 mM magnesium-acetate, 150 mM Na-acetate).
Relative quantification of sRNA from S. aureus by RT-PCR
RNA extraction was performed from mid (OD600 = 0.5) or post-
exponential phase (OD600 = 6) grown bacteria using RNeasy Plus
mini kit (QIAGEN) as described [53]. One mg of total RNA was
transcribed into cDNA using Reverse transcription system
(Promega). Subsequently, the cDNA was used as a template for
the real-time PCR amplification using a Realpex2 instrument
(Eppendorf) and the specific primers shown in Table S1. The
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amplification products were detected using SYBR Green. The
relative amounts of amplicons for each gene were determined
using quantitative PCR relative to an internal standard (gyrB
encoding Gyrase B subunit) as described [53]. The expression
levels of the sRNA were expressed as n-fold differences relative to
the calibrator.
In vivo ß-galactosidase assays
Translation fusions were constructed with plasmid pLUG220, a
derivative of pTCV-lac, a low-copy-number promoter-less lacZ
vector (Table S2). The whole leader region of mgrA (nts 2124 to +
258) mRNA (from P1 promoter) including 258 nts of the coding
sequence, was cloned downstream the rpoB promoter in frame with
lacZ. ß-galactosidase activity was measured four times on duplicate
cultures with the Enzyme Assay System (Promega).
Northern blots
Electrophoresis of total RNA (10 mg) was done on a 1% agarose
gel containing 25 mM guanidine thiocyanate and vacuum transfer
to nylon membrane. Hybridizations with specific digoxigenin-
labeled RNA probes complementary to mgrA mRNA or RsaA and
luminescent detection were carried out as described previously
[10]. For all experiments, we verified the quantity of 5S rRNA
using a digoxigenin-labeled RNA probe.
Gel retardation assays
Binding rate constant of RNAIII-mgrA mRNA complex was
measured as described previously [10]. Binding of 59 end-labeled
mgrA mRNA to a ten-fold excess of unlabeled RsaA or its
derivatives was performed at 37uC in TMN buffer. Samples were
withdrawn at various time points (0–10 min), added to gel
application buffer and loaded onto a native 5% polyacrylamide
gel under non denaturing conditions. The gel was run at 4uC and
constant voltage (300 V) for 3 h and subsequently dried. Bands
corresponding to the RsaA-mgrA mRNA complex and free RsaA,
respectively, were quantified using the SAFA algorithm. For
determination of the dissociation rate constant of RsaA-mgrA
mRNA complex, end-labeled mgrA mRNA was incubated with an
increased concentrations of WT RsaA or its variants for 15 min at
37uC in TMN buffer. All experiments were done four times.
Proteomics
Growth conditions, preparation of protein extracts, and
separation of proteins using two-dimensional (2-D) gel electropho-
resis concerted with protein identification by mass spectrometry
approach have been described in [20]. Experimental details are
given in the supplementary materials (Supplementary Protocol
S1).
Relative MgrA protein expression level was defined by a
spectral counting strategy (see Supplementary Protocol S1).
Triplicate protein extracts from HG001 (WT), DrsaA mutant
strain (LUG1630), and the same strain complemented with a
plasmid expressing RsaA, were analyzed in separate LC/MS
experiments and the MS/MS spectra number were compared for
each protein. In parallel to MgrA, we analyzed several ribosomal
proteins (L21, L22, L24) as internal controls of constitutively
expressed proteins.
Western blot analysis
Cell extracts from the post-exponential (OD600 = 4) phase of
growth were prepared from various staphylococcal strains as
described in Supplementary Protocol S1. The concentration of
total proteins from clear lysates was determined using the Bio-Rad
protein estimation kit and BSA as the standard. Equal amounts of
total cellular proteins were separated on 15% polyacrylamide-SDS
gels and transferred onto PVDF membranes. Blots were incubated
at 20uC with an appropriate dilution (1:1000) of anti-MgrA-
specific monoclonal for 1 h (generous gift from A. Cheung, USA),
followed by another 1 h incubation with a 1:2500 dilution of goat
anti-mouse peroxidase (HRP) conjugate. Prestained protein
standards were used for molecular mass estimations, and the gel
was stained by Coomassie blue to verify that the quantity of
proteins was homogenous in each sample. Each experiment was
repeated at least three times with different samples.
RNA structure probing using enzymes
RNAIII-mgrA mRNA formation was carried out at 37uC for
15 min in TMN buffer. Enzymatic hydrolysis was performed
either on cold mgrA (1 pmole) or 59 end-labeled RsaA (50000 cpm)
in 10 ml of TMN, in the presence of 1 mg carrier tRNA at 37uC for
5 min: RNase T1 (0.0025 units), RNase V1 (0.5 units), RNase T2
(0.05 U), RNase III (500 nM). Lead(II) induced cleavages were
performed on 59 end-labeled RsaA at 20uC in 20 ml of TMN
buffer containing 2 mg of carrier tRNA with 2.5 ml of different
concentrations of lead(II)-acetate (12, 40, and 80 mM) for 5 min at
37uC. The reactions were stopped with 5 ml of EDTA 0.1 M for
lead(II)-induced cleavages and all other reactions were stopped by
phenol extraction followed by RNA precipitation. The end-labeled
RsaA fragments were sized on 12% polyacrylamide/8 M urea slab
gels. For mgrA mRNA, the enzymatic cleavages were detected by
primer extension with reverse transcriptase [56].
Toeprinting assays
The preparation of the S. aureus 30S subunits, the formation of a
simplified translational initiation complex with mRNA, and the
extension inhibition conditions were described according to [57].
Experimental details are given in the supplementary materials
(Supplementary Protocol S1).
In vitro transcription-translation assays
The in vitro translation assays were carried out using the full-
length WT mgrA or mgrA-S1 or mgrA-S2 mRNAs and the
PURESYSTEMII classic kit (Cosmo Bio Co, Japon). All
constructs carry an additional sequence corresponding to the Flag
peptide, which was inserted at the 59 end of mgrA. The reaction
was done at 37uC for 1 h in the presence of 25 ml of the
commercial solution A and 10 ml of the commercial solution B in
the presence of 10 pmoles of mRNA. Experiments were also
carried out in the presence of increasing concentrations of WT or
mutant RsaA (5 to 30 pmoles). The tubes were placed on ice to
stop the reactions, and the proteins were detected by western blot
using antibodies against the FLAG tag.
Biofilm Crystal Violet Staining and Biofilm Ring Test
The biofilm formation was detected by tissue culture plate
method that allowed semi-quantitative measurement of biofilm
formation as described previously by Heilmann et al. [58]. All tests
were carried out three times and average OD value was calculated
for each strain and for negative controls. Experimental details are
given in the supplementary materials (Supplementary Protocol
S1).
The kinetics of early biofilm was evaluated by Biofilm Ring test
(BRT) (BioFilm Control, Saint Beauzire, France) as described [59].
This assay is based on the immobilization of magnetic beads
embedded by bacterial aggregates with enough strength to
overcome the magnetic attraction forces applied on them. Thus,
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in the absence of sessile cells, all the beads are gathered by a
magnet centered under the well, giving an easily detectable red
spot [59]. Three experiments with two repeats (2 wells per slide)
were performed per strain and per incubation time. Experimental
details are given in the supplementary materials (Supplementary
Protocol S1).
Quantification of PIA/PNAG production
The PIA/PNAG polysaccharide of biofilm was quantified by
the immuno-slot-blotting method with rabbit anti-PIA/PNAG
antiserum as described by Cuc¸arella et al. [60].
Quantification and visualization of the capsular
polysaccharides
Capsular polysaccharides type 5 (CP5) or 8 (CP8) were
quantified by the immuno-slot-blotting method with rabbit anti-
CP5 or anti-CP8 antisera, essentially as described by Luong et al.
[24]. CP8 production was determined by indirect immunofluo-
rescence. After culture for 8 h in BHI medium at 37uC, bacteria
were spotted in diagnostic slides. The slide was incubated with
rabbit anti-CP8 antiserum for 1 h at 37uC in humid chamber.
After 2 washes, the slide was incubated with secondary antibody,
AlexaFluor 647 goat anti-rabbit immunoglobulin G (Invitrogen,
Paisley, UK). Total bacteria were labeled with a 1:1 mixture of
vancomycin and vancomycin-Bodipy FL (VBFL) fluorochrome
(Invitrogen) at a concentration of 0.8 mg/ml for 15 min. Images
were analyzed with confocal microscopy Leica SP5 X (Leica,
Solms, Germany) and treated with Leica software: LAS AF Lite
(Leica Application Suite 2.6.0).
CP5 or CP8 were quantified by the immuno-slot-blotting
method with rabbit anti-CP5 or anti-CP8 antisera, essentially as
described by Luong et al. [24]. Experimental details are given in
the supplementary material (Supplementary Protocol S1).
Model of catheter infection in mice
The catheter infection model was performed essentially as
described by [61]. C57Bl/6 female mice (11–14 weeks old) were
purchased from Charles River Laboratories (Charles River,
Wilmington, USA) and maintained in pathogen-free conditions
at the ‘‘Plateau de Biologie Expe´rimentale de la Souris’’ (PBES,
Ecole Normale Supe´rieure de Lyon, Lyon, France). This study and
procedure were approved by the ‘‘Comite´ Rhoˆne-Alpes d’Ethique
pour l’Expe´rimentation Animale’’ (CECCAPP, Lyon, France).
Mice were anesthetized with 2–3% of isofluran. After depilating
and disinfecting the back of the mouse, a sterile catheter was
implanted subcutaneously on the back of each mouse. Twenty-five
microliters of PBS containing approximately 46104 bacteria
(Becker or Becker-DrsaA) were then injected into the catheter.
The wound was sewed by a clip. Each day, mice were weighed and
the size of the swelling was measured with an electronic caliper.
On days 3, 6 and 10, mice were euthanized by cervical dislocation,
the catheter and surrounding tissues were carefully removed and
transferred separately in sterile tubes for bacterial quantification by
plate counting as described. Experimental details are given in the
supplementary materials (Supplementary Protocol S1).
Bacteremia model
CD-1 female mice (8 to 10 weeks old) were obtained from
Charles River Laboratories and maintained in pathogen-free
conditions at the PBES. This study and procedure were approved
by the CECCAPP. Groups of six mice were inoculated intraper-
itoneally with 56106 CFU/mouse in 0.5 ml of PBS. After 1 and
3 h, mice were sacrificed and 4 ml of PBS were intraperitoneally
injected to recover the surviving bacteria. Blood samples were also
collected in heparinized tubes from intracardiac puncture. Spleen
and kidneys were collected after 24 and 48 h. After addition of
1 ml of NaCl 0,9%, organs were crushed with a homogenizer T18
basic. Bacterial quantification of all samples was performed by
plate counting.
Statistical analysis
All the data were expressed as mean 6 SD. The statistical
analyses were performed using GraphPad Prism 6 software. A
one-way analysis of variance was realized to test the results
obtained in mature biofilm quantification. Other data were
analyzed using Mann-Whitney test. A value of p,0.05, ,0.005
or ,0.0005 was considered to be statistically significant (*), highly
significant (**), or extremely significant (***), respectively.
Supporting Information
Figure S1 Effect of RsaA on the S. aureus proteome. (A)
2-D fluorescence difference gel electrophoresis (DiGE) performed
on HG001 and DrsaA-HG001 strains. Total protein extracts were
prepared from cultures performed at 37uC stopped at the
stationary phase of growth, and labeled with different cyanines.
Yellow spot, for unchanged proteins; green spot, protein synthesis
activated in strain expressing RsaA; red spot, protein synthesis
repressed in strain expressing RsaA. (B) Interpretation of the LC-
MS-MS data. A Spectral Counting (SpC) strategy was carried out
using the Mascot identification results and Proteinscape 3.1
package. The total number of proteins and spectra are given for
each assay. To normalize data, a correction factor was applied for
each condition according to the average spectra number for all
samples. Three independent experiments were done. In the second
table, the normalized spectral counts SpC for MgrA and for the
ribosomal protein L21 (RL21) are given and the data have been
normalized to the wild-type (WT) strain. STD: A statistical
analysis was performed to provide the mean and the standard
deviations, which are represented on the histogram. The data were
done on crude extracts prepared from late-exponential growth of
the WT (HG001), the DrsaA mutant strain (DrsaA), and DrsaA
mutant strain complemented with a plasmid expressing RsaA
under its own promoter (DrsaA/pl. rsaA).
(EPS)
Figure S2 Secondary structures of RsaA and of mgrA
mRNA. (A) RsaA secondary structure. The conserved nucleotides
are shown in red. The two regions of interaction (sites 1 and 2) are
enboxed. (B) Structure of the leader region of mgrA mRNA
expressed from the P2 promoter. The Shine and Dalgarno
sequence (SD) and the AUG codon are in red. (C) RNase III
cleavage assays on mgrA mRNA. Lanes 1–2: incubation controls
performed on mgrA mRNA in the absence (lane 1) or in the
presence of 250 nM RsaA (lane 2); lanes 3–5: RNase III (0.65 mM)
cleavage assays on mgrA in the presence of increasing concentra-
tions of RsaA (25 nM, lane 4; 50 nM, lane 5; 250 nM, lane 6);
lane 7: RNase III (0.65 mM) cleavage assay performed on mgrA
bound to RsaA (250 nM) in a buffer containing Ca2+ instead of
Mg2+. Lanes 8–12: same legend as for lanes 3–7, respectively
except that the concentration of RNase III was 0.35 mM. Lanes U,
C, G, A: sequencing ladders.
(EPS)
Figure S3 Effect on RsaA on ica-dependent biofilm
formation. Dot-blot analysis of PIA/PNAG polysaccharide
accumulation in wild-type strains and their corresponding DrsaA
mutant strains and the same strains complemented with a plasmid
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expressing RsaA. Growth was performed in BHI medium
containing 0.25% glucose for 16 h. Standardized bacterial
suspensions were treated with proteinase K, and 1/5 serial
dilutions were spotted on nitrocellulose membrane. PIA/PNAG
production was detected with an anti-PIA/PNAG antibody.
(EPS)
Figure S4 RsaA affects opsonophagocytosis. Mortality of
bacteria after opsonophogocytosis assay. Each S. aureus strain was
mixed with the same quantity of human serum and PMNs for
30 min at 37uC. Sample dilutions were made in sterile deionized
water, and bacterial killing was estimated by plating the diluted
samples in duplicate on GP. The cell killing was defined as the
reduction in CFU/ml after 30 min compared with that at time
zero. The graphic represents the % of mortality for each strain of 3
to 5 individual experiments. Three different S. aureus backgrounds
(HG001, Newman, Becker) were analyzed, as well as their
corresponding DrsaA mutant strains and the same mutant strains
complemented with a plasmid expressing RsaA.
(TIFF)
Figure S5 The impact of RsaA on virulence in in vivo
bacteremia model. An in vivo bacteremia model has been used
to mimic an acute infection with Becker and Newman back-
ground. (A, C, D) 56106 bacteria in 500 ml were injected into
peritoneal cavity. After 1 h (C) and 3 h (A, D), viable bacteria into
peritoneal cavity were removed, enumerated by serial dilutions
and plate counting on agar plates. (B, E, F) Blood samples were
also collected in heparinated from intra-cardiac puncture and
bacteria were enumerated by serial dilutions and plate counting on
agar plates. (G, H) After 24 and 48 h, spleen was collected in the
two strain backgrounds (Becker and Newman) and their
corresponding DrsaA mutant strains, and bacteria were enumer-
ated. The results were expressed in number of CFU/ml. Each
point designates the number of bacteria for each mouse and the
black line represents the mean of each tested condition. Statistical
differences * (p,0.05), ** (p,0.005) and *** (p,0.0005) between
each groups were obtained by using Mann Whitney test.
(TIFF)
Figure S6 Expression of RsaA in reference strains and
clinical isolates. The expression of RsaA was quantified and
normalized to the level of gyrB mRNA expression after in vitro
culture to the mid- or late-exponential phase for 16 clinical isolates
(A) and 6 reference strains (B).
(EPS)
Protocol S1 Supplementary Material and Methods.
(DOC)
Table S1 In silico prediction of base pairings between
RsaA and mRNAs.
(DOCX)
Table S2 Strains and plasmids.
(DOCX)
Table S3 Primers used in this study.
(DOCX)
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